Research Analysts Offer Predictions for Mativ Q3 Earnings

Mativ Holdings, Inc. (NYSE:MATV - Free Report) - Equities researchers at Sidoti Csr raised their Q3 2025 earnings per share (EPS) estimates for Mativ in a report released on Friday, May 9th. Sidoti Csr analyst D. Harriman now forecasts that the company will post earnings of $0.31 per share for the quarter, up from their prior forecast of $0.28. The consensus estimate for Mativ's current full-year earnings is $1.15 per share. Sidoti Csr also issued estimates for Mativ's Q4 2025 earnings at $0.20 EPS, Q1 2026 earnings at $0.19 EPS, Q2 2026 earnings at $0.31 EPS, Q3 2026 earnings at $0.26 EPS and Q4 2026 earnings at $0.20 EPS.

Mativ (NYSE:MATV - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The company had revenue of $484.80 million for the quarter, compared to the consensus estimate of $470.30 million. Mativ had a positive return on equity of 3.86% and a negative net margin of 2.46%.

Separately, Stifel Nicolaus upgraded Mativ from a "hold" rating to a "buy" rating and reduced their target price for the stock from $15.50 to $10.00 in a research report on Monday, March 24th.

Mativ Stock Up 1.4%

Shares of MATV traded up $0.09 on Monday, reaching $6.36. The company's stock had a trading volume of 573,603 shares, compared to its average volume of 589,308. Mativ has a twelve month low of $4.34 and a twelve month high of $19.96. The company has a current ratio of 2.40, a quick ratio of 1.29 and a debt-to-equity ratio of 1.28. The firm has a fifty day moving average of $5.58 and a 200-day moving average of $9.08. The stock has a market capitalization of $346.73 million, a PE ratio of -7.07, a PEG ratio of 1.08 and a beta of 0.61.

Mativ Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, May 23rd will be given a $0.10 dividend. The ex-dividend date is Friday, May 23rd. This represents a $0.40 dividend on an annualized basis and a dividend yield of 6.29%. Mativ's dividend payout ratio is currently -4.88%.

Institutional Investors Weigh In On Mativ

Institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC lifted its holdings in Mativ by 227.5% during the third quarter. Barclays PLC now owns 102,836 shares of the company's stock valued at $1,748,000 after purchasing an additional 71,436 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Mativ by 8.3% in the third quarter. Franklin Resources Inc. now owns 34,362 shares of the company's stock valued at $574,000 after purchasing an additional 2,648 shares during the period. JPMorgan Chase & Co. raised its stake in Mativ by 44.8% in the third quarter. JPMorgan Chase & Co. now owns 196,822 shares of the company's stock worth $3,344,000 after buying an additional 60,930 shares in the last quarter. KBC Group NV boosted its stake in Mativ by 93.2% in the fourth quarter. KBC Group NV now owns 4,787 shares of the company's stock valued at $52,000 after acquiring an additional 2,309 shares in the last quarter. Finally, Empowered Funds LLC lifted its stake in shares of Mativ by 34.5% during the fourth quarter. Empowered Funds LLC now owns 301,432 shares of the company's stock worth $3,286,000 after buying an additional 77,383 shares during the period. Institutional investors own 94.95% of the company's stock.

Mativ Company Profile

Mativ Holdings, Inc, together with its subsidiaries, manufactures and sells specialty materials in the United States, Europe, the Asia Pacific, the Americas, and internationally. The company operates through two segments, Advanced Technical Materials and Fiber-Based Solutions. The Advanced Technical Materials manufactures and sells various engineered polymer, resin and fiber-based substrates, nets, films, adhesive tapes, and other nonwovens for the filtration, protective solutions, release liners, and healthcare end-markets.